Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies
HIV Medicine · 2024-07 · 25 (7) · 873-884
DOI: 10.1111/hiv.13643 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift HIV Medicine, online erschienen am 17.05.2024. Verfasst von C Katlama und 14 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, INSERM-Sorbonne Universités, Paris, France. Hauptthemen laut MEDLINE: Pyridones, Oxazines, Heterocyclic Compounds, 3-Ring, HIV Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ViiV Healthcare.
Abstract (Originalsprache)
Objectives
Women represent >50% of people with HIV globally but have historically been underrepresented in clinical trials. We evaluated the efficacy and safety of switching to dolutegravir/lamivudine (DTG/3TC) vs continuing their current antiretroviral regimen (CAR) by sex assigned at birth (female and male) in virologically suppressed adults with HIV‐1 without prior virological failure in a pooled analysis of two randomized controlled trials.
Methods
This analysis included 48‐week data from the phase 3 TANGO and SALSA studies. Primary and key secondary endpoints included proportions of participants with HIV‐1 RNA ≥50 and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AP-HP, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, INSERM-Sorbonne Universités, Paris, France.
- Holdsworth House Medical Brisbane, Fortitude Valley, Queensland, Australia.
- Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
- Hospital Universitario Ramón y Cajal, Madrid, Spain.
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy.
- Axess Sexual Health, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Förderung
- ViiV Healthcare
Zitieren
APA
Katlama, C., Bisshop, F., Bogner, J., Pérez Elías, M. J., Di Giambenedetto, S., Clarke, E., Hodder, S., Nwokolo, N., Ait-Khaled, M., Oyee, J., Grove, R., Wynne, B., Okoli, C., Jones, B., & Kisare, M. (2024). Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies. HIV Medicine, 25(7), 873-884. https://doi.org/10.1111/hiv.13643
Vancouver
Katlama C, Bisshop F, Bogner J, Pérez Elías MJ, Di Giambenedetto S, Clarke E, et al. Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies. HIV Medicine. 2024;25(7):873-884. doi:10.1111/hiv.13643
BibTeX
@article{Katlama2024,
author = {Katlama, C and Bisshop, F and Bogner, J and Pérez Elías, M J and Di Giambenedetto, S and Clarke, E and Hodder, S and Nwokolo, N and Ait-Khaled, M and Oyee, J and Grove, R and Wynne, B and Okoli, C and Jones, B and Kisare, M},
title = {Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies},
journal = {HIV Medicine},
year = {2024},
volume = {25},
number = {7},
pages = {873--884},
doi = {10.1111/hiv.13643}
}
EUVIMED